A detailed history of Epiq Capital Group, LLC transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Epiq Capital Group, LLC holds 739,426 shares of CYTH stock, worth $510,203. This represents 0.18% of its overall portfolio holdings.

Number of Shares
739,426
Previous 817,270 9.52%
Holding current value
$510,203
Previous $1.04 Million 43.68%
% of portfolio
0.18%
Previous 0.39%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.64 - $1.38 $49,820 - $107,424
-77,844 Reduced 9.52%
739,426 $584,000
Q2 2024

Aug 09, 2024

SELL
$1.16 - $1.53 $42,392 - $55,913
-36,545 Reduced 4.28%
817,270 $1.04 Million
Q1 2024

May 14, 2024

BUY
$1.39 - $1.9 $1.19 Million - $1.62 Million
853,815 New
853,815 $1.19 Million

Others Institutions Holding CYTH

About Cyclo Therapeutics, Inc.


  • Ticker CYTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 8,439,440
  • Market Cap $5.82M
  • Description
  • Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...
More about CYTH
Track This Portfolio

Track Epiq Capital Group, LLC Portfolio

Follow Epiq Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Epiq Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Epiq Capital Group, LLC with notifications on news.